Kornimate/medical-research-clean huggingface dataset:
evaluation of rso2 between frontal lesion area and normal area of brain by nirsitx using nirs in acute ischemic stroke patients.

Conditions: Acute Ischemic Stroke Patients

Summary: the clinical trial is for acute ischemic stroke patients measuring cerebral oxygen saturation (rso2) values using pulse oximeter of near-infrared spectroscopy in the frontal lesion area and normal area of brain. the purpose of the clinical trial is to compare differences in cerebral oxygen saturation values, and the efficacy and safety are evaluated through additional exploratory clinical trials.


Eligibility criteria:
inclusion criteria: * adults over age 19 * patients diagnosed with acute ischemic stroke within 7 days of symptom onset * patient's condition confirmed to have an acute ischemic stroke and also brain blood vessels condition confirmed through brain imaging such as brain ct/cta/ct perfusion and brain mri/mra * patients voluntarily agree to participate and scheduled to participate in this clinical trial * patients willing to comply with the clinical trial protocol exclusion criteria: * patients without brain imaging result * patients diagnosed with jaundice (hyperbilirubinemia) with abnormal skin color - patients who find it difficult to wear medical devices for clinical trial on their foreheads * patients who has skull fractures of external shape not maintained normal * patients who does not agree to participate in this clinical trial * patients who are currently participating in another clinical trial or have participated in another clinical trial within 30 days of the screening date * patients who is determined from investigator that participating is inappropriate because it may affect the results of the clinical trial or ethically
immune memory foll pry vaccination with dtpw-hbv/hib vaccine formulation; immuno & reacto of booster dose at 15-18 mths

Conditions: Hib Disease; Hepatitis B; Pertussis; Prophylaxis of Diphtheria; Tetanus

Summary: to assess the anti-prp antibody response one month after vaccination in the groups receiving a fourth consecutive dose of two formulations of dtpw-hbv/hib vaccine

all subjects were previously primed with one of the two formulations of the combined dtpw-hbv/hib vaccine. at the age of 10 months, 50% of each group received a plain prp challenge to assess the immune memory to prp. in this booster study in the second year of life, all subjects who received dtpw-hbv/hib and plain prp will receive dtpw-hbv as a booster vaccination. all other subjects will receive as booster the same vaccine they received in the primary vaccination study.

Eligibility criteria:
inclusion criteria * subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol. * a male or female of at least 15 months of age at the time of the booster vaccination, who had previously received 3-dose primary vaccination and, if applicable, plain-prp vaccination. * free of obvious health problems as established by medical history and clinical examination before entering the study. exclusion criteria for enrolment * use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the dose of study vaccine, or planned use during the study period. * planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before and ending 30 days after administration of study vaccines with the exception of oral polio vaccine (opv). * chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the booster dose. * previous booster vaccination against diphtheria, tetanus, pertussis, hepatitis b or hib with the exception of plain prp challenge. * any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination.
adherence to oral anticoagulants in patients with atrial fibrillation

Conditions: Oral Anticoagulant; Adherence

Summary: the rhythm disorders of atrial fibrillation (af) require continuous treatment with anticoagulants to prevent stroke. the introduction of direct oral anticoagulants (doacs) quickly supplanted the administration of anti-vitamin k (avk) which presented an elevated risk of hemorrhage. however, the adherence of the treatments by the oad is very poor, several studies show that 30 to 50% of the patients fail to adhere to their treatment very soon after starting it. in a recent study, in the united states, using data collected between 2010 and 2014 in more than 60,000 patients with af, yao et al show that less than 50% of patients can be considered "adherent". they conclude in this study that adherence to anticoagulation is low in practice, although it may be slightly improved with doacs. more recently a meta-analysis shows that 66% of patient treated by doacs were considered adherent (pdc \> 80 %). in addition, therapeutic adherence seems to be essential in patients with a cha2ds2-vasc score ≥2. indeed improving adherence reduces the risk of stroke occurrence. the investigators propose to evaluate during an interview in the pharmacy, the adherence of ambulatory patients (at the time of their renewal of treatment at the pharmacy) by the "proportion of days covered" (pdc) of the treatment by aod, and by a simplified questionnaire and to define a profile of patients treated for af at risk of nonadherence to aod (pdc adherence prediction score). the investigators perform an observational, prospective multicenter study , in which patients adherence will be quantified in a standardized method.


Eligibility criteria:
inclusion criteria: * over the age of 18 * consultation in the community pharmacy * long-term treatment for at least six months with an doacs. * patients able and agreeing to participate in the evaluation of their adherence exclusion criteria: * treatment by doacs limited in the duration * contra-indications of doacs

Keywords: direct oral anticoagulant adherence proportion of days covered adherence questionary girerd adherence questionary
assessing antibiotic induced liver injury for stratification of tuberculosis patients

Conditions: Drug-Induced Liver Injury; Anti-Tuberculous Drug Reaction; Tuberculosis

Summary: a panel of highly sensitive circulating biomarkers for acute liver injury have been identified and demonstrated to identify liver injury on first presentation to hospital before standard tests are elevated in patients with paracetamol overdose. the investigators wish to test these biomarkers in patients with active and latent tuberculosis to see if they can be used to stratify patients undertaking anti-tuberculosis drug therapy. anti-tuberculosis drug induced liver injury is the most frequent side-effect of anti-tuberculosis therapy, affecting 2-5% of tuberculosis patients seen at the royal infirmary edinburgh and hindering their effective treatment. patients will be recruited from the tb out-patient clinic at the royal infirmary edinburgh. blood samples will be taken every time the patient visits the clinic and also retrieved from the biochemistry lab. the biomarkers in the blood samples will be analysed to determine if they rise in patients who develop liver injury.

to improve patient stratification, the investigators have developed a panel of novel circulating liver specific and mechanistic biomarkers that report early acute liver injury. such biomarkers are needed as current early biomarkers of liver injury lack sensitivity and specificity. the panel of biomarkers either have enhanced liver specificity or provide mechanistic insights. currently, antituberculosis drug-induced liver injury (atdili) is the most frequent side-effect of anti-tuberculosis therapy and this hinders the effective treatment of tb, as it means that treatment regimens are not completed. at present, the risk of atdili means that monitoring of liver function is required, with levels of alt measured monthly. if levels of alt rise to 2-5x the upper limit of normal levels (uln) and the patient is unwell the frequency of monitoring is increased to biweekly monitoring. antibiotic therapy is only changed if levels of alt remain greater than 3xuln, the patient continues to display symptoms and there is a positive causality assessment that the anti-tuberculosis drugs are causing atdili. this project will recruit patients taking antituberculosis drugs and determine the diagnostic and prognostic value of the biomarker panel, in relation to liver injury as a result of anti-tuberculosis therapy.

Eligibility criteria:
inclusion criteria: * patients undergoing treatment for tuberculosis * patients with the capacity to give consent exclusion criteria: * patients unable to give informed consent * patients who refuse to take part * hiv positive patients
the study of the prevalence of helicobacter pylori infection among hiv/aids cohort

Conditions: HIV

Summary: the purpose of the study is to investigate the prevalence of helicobacter pylori infection among the hiv/aids group. the study will screen the patients who were confirmed hiv/aids in kaohsiung medical university hospital and collect the cases who were suspicious of helicobacter pylori infection.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of hiv * the person who have stomach pain, vomiting or nausea

Keywords: hiv, aids, helicobacter pylori
weaning from mechanical ventilation in the icu

Conditions: Quality of Life

Summary: the investigators objective is to assess quality of life and functional outcome in patients requiring short-term mechanical ventilation. additionally, the investigators plan to measure the recovery of peripheral muscle strength and respiratory muscle strength during recovery.


Eligibility criteria:
inclusion criteria: * icu patients who require mechanical ventilation for at least 2 days * the ability to speak english * willing to participate exclusion criteria: * patients who require mechanical ventilation at home before hospitalization * patients previously requiring mechanical ventilation at an ltac facility

Keywords: sf-36 katz
gabapentin for postoperative pain management after cardiac surgery with median sternotomy

Conditions: Pain, Postoperative

Summary: in this study we will focus on the postoperative recovery. a successful postoperative recovery should bring the patient to at least to the pre-surgical level. this can probably be achieved by a multimodal approach where at least postoperative pain and ponv are managed. the surgical injury results in immobilisation which again can result in impaired cardiac, respiratory and musculoskeletal system. pain relief is a prerequisite for mobilisation and an early return to the pre-surgical level. the preferred drugs for postoperative pain management are opioids. although opioids are known to be an effective analgesia, they have a series of side effects: nausea, vomiting, constipation, respiratory deficiency, delirium among others. gabapentin has been tested for post operative pain. randomized clinical trials have reported a significant better pain scores with gabapentin in several studies -most of them restricted to the postoperative period in the post-anaesthesia care unit in many different kind of surgeries. we want to test if gabapentin can be used instead of opioids for treatment of postoperative pain after heart surgery by median sternotomy.


Eligibility criteria:
inclusion criteria: 1. patients scheduled for elective cardiac surgery with median sternotomy at the department of cardiac surgery, aarhus university hospital, skejby. 2. patients older than 18 years. exclusion criteria: 1. patients unable to cooperate. 2. known allergy for gabapentin or opioids. 3. acute pancreatitis 4. history of gastric or peptic ulcer. 5. history of alcohol or drug abuse. 6. chronic pain or daily intake of analgesics or corticosteroids. 7. gastrointestinal obstruction 8. impaired liver function. 9. impaired kidney function. 10. previous operation with median sternotomy 11. pregnant women
caspofungin based combined anti-fungal therapy for proven or probable invasive fungal infection

Conditions: Leukemia; Transplantation, Hematopoietic Stem Cell

Summary: in this prospective phase ii observational study, we plan to assess the efficacy and tolerability of caspofungin based combined anti-fungal therapy for proven or probable ifi in a group of patients received allo-hsct transplantation with high risk of ifi: hla matched unrelated donor or mismatched donor conditioning with atg containing regimen or present iii-iv agvhd or extensive gvhd undergoing high-dose steroid treatment.

patients will recieve caspofungin with either voriconazole or amphotericin b as combination therapy for fungal infection

Eligibility criteria:
inclusion criteria: * adult patient undergoing allogeneic hematopoietic stem cell transplantation * age 18-55 years * with inform consent * no contraindication for allogeneic transplantation: active infection, allergy to flu/bu/ctx, liver and renal function damage * hla mismatched related (3\~5/6) or unrelated donors (at least 8/10) * proven or probable ifi exclusion criteria: * age less than 18 years or over 56 years * hla mismatched related donor * liver function/renal function damage (over 2 x upper normal range) * with mental disease

Keywords: caspofungin ifi allogeneic hematopoietic stem cell transplantation
in vitro evaluation of the anti-fibrotic activity of adipose tissu-derived stromal vascular fraction used as a medicinal treatment for scarred vocal folds

Conditions: Vocal Cord Injuries

Summary: this is a single-center, prospective study, aimed at investigating the anti-fibrotic in vitro activity of the stromal vascular fraction of patients with scarred vocal cord.

this single-center, prospective study will last 28 months and will be carried out in two stages: 1. comparison of the in vitro anti-fibrotic activity and production/management circuit of different cell therapy products derived from adipose tissue obtained from healthy donors (n=8) \[secondary objective\] during the first 12 months of the project. 2. evaluate the association between the in vitro anti-fibrotic activity of fraction vascular fraction (fvs) samples and the clinical improvement obtained with the same sample autologously injected into a patient in the cellcordes2 trial (minimum recruitment n=10, cellcordes2 biocollection) \[primary objective\]. this second stage will be carried out between m12 and m24 to optimize the number of patients to be included.

Eligibility criteria:
inclusion criteria for patients included in the cellcordes 2 clinical trial * voice handicap index \> 50/120 * scarring, congenital (sulcus) or post-phonosurgery vocal cords * vibratory anomalies in the middle third of one or both vocal cords on stroboscopy * a minimum of six months after the initial surgery * patients aged 18 to 70 years * good general health * negative pregnancy test and contraception for women of childbearing age signature of consent for the storage and use of biological samples inclusion criteria for healthy donnors: * liposuction surgery for aesthetic reasons * bmi between 18 and 27 * no chronic diseases * non-opposition to the use of surgical waste for research purposes after freezing in a biological collection exclusion criteria: for all patients: * refusal or inability to comply with the study procedures * minors * pregnant or breastfeeding women * legally protected adults (under guardianship or curatorship) * individuals residing in a healthcare or social establishment emergency situations * individuals deprived of liberty * detainees * individuals not covered by a social security scheme * use of an experimental drug in the last three months * contraindication to local anesthesia * anticoagulant treatment * coagulation disorders (tp \ 1.2) * premenopausal women of childbearing age without contraception * lack of or refusal of informed consent exclusion criteria for patients in the cellcordes 2 clinical trial: * patients refusing pre- and post-operative speech therapy * history of malignant lesions or severe dysplasia on the scarred vocal cord * history of laryngeal papillomatosis * active infectious diseases * positive serology for hiv1 and 2, p24 ag, hcv abs, hbs ag, hbc abs, htlv and ii abs, tpha * need for perioperative antibiotic prophylaxi
d-serine and cognitive remediation in schizophrenia

Conditions: Schizophrenia

Summary: the investigators will test the effects of 3 days of d-serine (dsr) on auditory plasticity in a sensory based remediation (sbr) paradigm

we will enroll 8 subjects in an open label, three session pilot in patients will receive three sessions of tone matching sbr. 5 subjects will receive d-serine (60mg/kg) taken 1x each week during the sbr sessions. subjects will receive study drug 30 minutes prior to session. 3 subjects received no intervention

Eligibility criteria:
inclusion criteria: * 18 to 64 years old, * iq≥85 and * estimated glomerular filtration rate (gfr) ≥60. all oral and depot antipsychotics (with the exception of clozapine) are allowable. patients must be on their antipsychotic medication for 1 month and stable on dose of antipsychotic and adjunctive medications for 2 weeks prior to study entry. exclusion criteria: * history of neurological visual or hearing impairment, * active suicidal ideation on the columbia suicide severity rating scale (c-ssrs), * current alcohol or drug abuse (\<1 month) or substance dependence (\<4 months). all women of child-bearing potential must have a negative urine pregnancy test at the baseline visit. we require an iq of ≥85 to ensure that subjects will have a capacity to learn. in our cross-sectional studies, we have observed an iq≥85 in over 90% of candidates, suggesting that this is not an overly restrictive criterion.

Keywords: cognitive remediation
anti-tnf therapy in danish patients with inflammatory bowel diseases in clinical practice

Conditions: Crohn's Disease; Ulcerative Colitis; Inflammatory Bowel Disease

Summary: can genetic markers be used to predict anti-tnf response? a cohort was established to identify snps associated with anti-tnf therapy in patients with inflammatory bowel disease.


Eligibility criteria:
inclusion criteria: * cd or uc, treated with anti-tnf exclusion criteria: * missing data
diagnostic accuracy study of indocyanine green for parathyroid perfusion assessment

Conditions: Thyroid Cancer; Thyroid Goiter; Graves Disease

Summary: this study aims to develop a standardized universal imaging protocol for icg-guided fluorescent total thyroidectomy, including quantitative evaluations of the fluorescent signal. therefore, patients will undergo thyroid surgery (total thyroidectomy) with the use of icg fluorescence.

background thyroid surgery volume continues to increase worldwide over the past few decades. during a total thyroidectomy (ttx), the ultimate goal is to remove all thyroid tissue, whereas damage to adjacent tissue is prevented. however, iatrogenic hypoparathyroidism, as a result of surgical removal or damage to the parathyroid glands, occurs in approximately 30% of the cases. in 2016 near-infrared fluorescence guided surgery with indocyanine green (icg) was proposed for visualizing viability and blood supply of parathyroid glands during ttx. icg can visualize tissue perfusion, since it becomes completely and permanently fixed to plasma proteins once in the bloodstream, and circulates in the intravascular compartment only. however, one of the limitations of icg imaging is the subjectivity of the interpretation of fluorescence, which makes the assessment of images inconsistent among studies. there is a clear need for standardization of the evaluation of the perfusion with icg, since visual evaluation of the fluorescent signal of icg is not sufficient to reliably predict the perfusion of parathyroid glands. main research question to develop a standardized universal imaging protocol for icg-guided fluorescent total thyroidectomy including quantitative evaluations of the fluorescent signal. design this will be a proof-of-concept , prospective cohort study of patients undergoing a total thyroidectomy with icg-guided fluorescent surgery to evaluate tissue perfusion the main study endpoint is quantification of the fluorescent signal of icg. secondary outcomes are data from surgery, postoperative lab values (including calcium, pth, albumin) and postoperative medication use.

Eligibility criteria:
inclusion criteria: 1. patients ≥ 18 years 2. patients undergoing total thyroidectomy as surgical procedure for thyroid cancer, graves' disease or goiter 3. patients are eligible for surgery 4. patients are mentally competent and are able and willing to comply with study procedures 5. written informed consent exclusion criteria: 1. patients with a known allergy to icg or iodinated contrast 2. pregnant or lactating women 3. patients with previous neck surgery

Keywords: thyroid surgery indocyanine green (icg) hypoparathyroidism
correlation of serum ca19-9 levels with levels in saliva and urine of patients with ductal adenocarcinoma of the pancreas

Conditions: Carcinoma, Pancreatic Ductal

Summary: ductal adenocarcinoma of the pancreas is the fifth leading cause of cancer related deaths in the european union. tumor markers ca19-9 and carcinoembryonic antigen are important components in decision making and follow-up of patients diagnosed with this disease. these tumor markers were found to be elevated not only in the serum but also in other body fluids in patients with malignant lesions of the parotid gland and the urinary tract. the authors have described in a previews small preliminary study a positive and a strong linear correlation between the levels of ca19-9 in urine and saliva with those presented in the serum of patients with ductal adenocarcinoma of the pancreas. the current study seeks to enlarge the study population to confirm the previous results and standardize the measured levels of ca19-9 in these body fluids.


Eligibility criteria:
inclusion criteria: patients: * proven diagnosis of ductal adenocarcinoma of the pancreas * elevated levels of ca19-9 * possible elevated levels of cea exclusion criteria: controls: * previous diagnosis of malignancy

Keywords: antigen, ca-19-9 salivas body fluids